Drug Database
TE

teriparatide (Xinfutai Pro)

✓ Approved

Shenzhen Salubris Pharmaceuticals Co., Ltd. · PTH1R · Recombinant Proteins

What is teriparatide?

teriparatide is a recombinant proteins developed by Shenzhen Salubris Pharmaceuticals Co., Ltd.. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesXinfutai Pro
CompanyShenzhen Salubris Pharmaceuticals Co., Ltd.
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Shenzhen Salubris Pharmaceuticals Co., Ltd.

Mechanism of Action

Molecular Targets

teriparatide acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

teriparatide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedAnalytical methods : advancing methods and applications2026-10-16

Insights into the degradation behaviour of tucatinib under stress conditions using liquid chromatography high resolution tandem mass spectrometry.

Prasad Kollu Sai Ram SR, Seema Rayeesa R, Swain Debasish D

Tucatinib is a kinase inhibitor drug used to treat unresectable or metastatic HER-2 positive breast cancer in combination with Trastuzumab and Capecitabine. Forced degradation studies assess the inherent stability of pharmaceutical compounds, while LC-MS/MS facilitates the identification and characterization of the resulting degradation products. In the present study, the stability of Tucatinib (TCB) was investigated under various stress conditions (hydrolytic, photolytic, thermal, and oxidative conditions). It was demonstrated that TCB was susceptible to hydrolytic (acid, base, and neutral) as well as oxidative degradation, yielding 11 degradation products, of which 9 are reported for the first time. A validated UHPLC method was developed using an Agilent Eclipse Plus C18 (4.6 × 150 mm, 5 µm) column with gradient elution using 0.1% formic acid in water and methanol as mobile phases. Mass characterization of the degradation products was carried out on an Exploris 120 Orbitrap mass spectrometer using the same chromatographic conditions. Also, degradation kinetics was assessed to define the trend followed by TCB under different stress conditions. Thus, the present study effectively presents a detailed degradation profile of TCB, and the developed method finds its use for the routine analysis of TCB and formulation development in bulk and dosage forms.

PMID 42885763
Read full article →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-10-16

Achieving High Spatial Resolution Transmission Electron Microscopy Studies in Closed Liquid Cells.

Guo Siqi S, Sun Hongyu H, Shu Le L, Ge Xuejin X et al.

Liquid cell transmission electron microscopy (LCTEM) is a rising technique for probing dynamic processes and structural transformations in liquid environments at the nanoscale. However, its broader application is largely constrained by limited spatial resolution, which arises from electron scattering by the encapsulating membranes and the liquid layer. Recent advances in instrument design, micro-electro-mechanical system (MEMS)-based cells, and ultrathin window materials have substantially improved imaging quality, yet achieving atomic-scale resolution in liquids remains a formidable challenge. This review provides a comprehensive overview of such strategies developed to enhance the spatial resolution of LCTEM, emphasizing the roles of liquid layer thickness, MEMS design, and cell configuration. We highlight representative approaches, such as reducing liquid and membrane thicknesses, optimizing MEMS architectures, and employing grid-based liquid cells, and discuss their underlying mechanisms and recent progress. Finally, we outline current challenges and future opportunities for achieving high-resolution, multifunctional LCTEM systems capable of capturing dynamic processes in realistic liquid environments.

PMID 42885387
Read full article →
PubMedMini reviews in medicinal chemistry2026-10-16

Phosphodiesterase 4 (PDE4) Inhibitor in Atopic Dermatitis: Impact of Nanocrisaborole on Biopharmaceutical Performance and Treatment Outcomes.

Alam Md Shoaib MS, Shafiq-Un-Nabi Sheikh S, Gayathri Veeraraghavan V, Maanvizhi Saba S et al.

The skin condition in atopic dermatitis, commonly referred to as eczema, is characterized by dry, itchy, and inflamed skin. Eczematous lesions frequently present with itching, irritation, broken skin, oozing, and crusting. Due to weakened immunity, patients with atopic dermatitis are more susceptible to developing additional conditions such as asthma and hay fever. Topical treatment of atopic dermatitis, including the use of promising PDE4 inhibitors such as crisaborole, is limited in its ability to permeate deeper into the skin due to poor physicochemical properties, including low aqueous solubility and difficulty in penetrating the epidermis. The delivery of existing therapeutics, such as crisaborole, using nanotechnology is a promising approach to overcome these limitations. Moreover, understanding the chemistry, structure-activity relationship, physicochemical properties, and stability of crisaborole is essential to ensure the quality, safety, and therapeutic efficacy of the active pharmaceutical ingredient during the development of novel pharmaceutical products. The present manuscript comprehensively discusses the significance of PDE4 inhibitors, specifically crisaborole, in the management of atopic dermatitis and the utilization of nanotechnology to evaluate its impact on biopharmaceutical performance and therapeutic outcomes. Furthermore, the detailed chemistry, structure-activity relationship, and metabolic fate of crisaborole are discussed to understand the stability of nanocrisaborole during its shelf life as a novel pharmaceutical product.

PMID 42885726
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Ultrasound-Assisted Deep Eutectic Solvent Extraction of Flavonoids from Hovenia dulcis Thunb: Optimization, Phytochemical Profiling, and Antioxidant and Anti-Inflammatory Activity Evaluation.

Zhou Lei L, Li Haixin H, Zhou Xu X, Zou Xueying X et al.

Hovenia dulcis Thunb. is a traditional medicinal and edible plant that is widely recognized for its hepatoprotective and hangover-alleviating properties, which are largely attributed to its rich flavonoid composition. The aim of this study was to develop an environmentally friendly ultrasonic-assisted deep eutectic solvent (UAE-DES) extraction method for the efficient extraction of bioactive flavonoids from Hovenia dulcis Thunb. A Box-Behnken design (BBD) was employed to systematically optimize the extraction parameters. Under optimal conditions (water content of 36%, liquid-to-solid ratio of 42:1 mL/g, extraction time of 42 min), the extraction yield reached a maximum of 9.09 ± 0.04%. Following purification using AB-8 macroporous resin, the phytochemicals were comprehensively characterized by UPLC-Q-Exactive Orbitrap-HRMS. A total of 12 flavonoids were identified. Bioassays demonstrated that the purified flavonoids exhibited strong, dose-dependent antioxidant activity against DPPH and ABTS radicals in vitro. Furthermore, the extract demonstrated significant anti-inflammatory activity by markedly inhibiting the excessive production of nitric oxide (NO) in RAW 264.7 macrophages induced by lipopolysaccharide (LPS), whilst exhibiting no cytotoxicity within the tested concentration range (0.06-0.96 mg/mL). These findings strongly confirm that the optimized UAE-DES method is a sustainable and efficient strategy for extracting structurally intact and pharmacologically active flavonoids from Hovenia dulcis Thunb, highlighting its immense potential for future applications in the functional food and pharmaceutical industries.

PMID 42883192
Read full article →
PubMedCancers2026-10-16

Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.

Mansour Hicham H, Mazouji Omayma O, El Hammouti Ayman A, Alloubi Ihasane I et al.

Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide, representing a major public health challenge. Although low-dose computed tomography is currently the standard screening method for high-risk individuals to reduce mortality, its clinical performance is limited by false-positive findings and restricted accessibility. Emerging biomarker-based liquid biopsy offers a promising non-invasive approach for cancer detection. This narrative review provides a critical overview and evaluation of clinically endorsed liquid biopsy applications for guiding treatment in advanced-stage lung cancer, as well as investigational advances in liquid biopsy for early cancer detection. We also address challenges of current liquid biopsy technologies, the integration of artificial intelligence, implementation improvements, and future perspectives for their adoption into routine clinical practice. To complement this narrative review, a structured search of the ClinicalTrials.gov registry was performed to identify clinical trials evaluating liquid biopsy in lung cancer. Current evidence supports the clinical use of liquid biopsy for molecular profiling and treatment selection in advanced non-small cell lung cancer (NSCLC), whereas its application in early detection, screening, and minimal residual disease (MRD)-guided management remains investigational and requires further prospective validation. Overall, liquid biopsy represents a promising complementary approach to advance precision oncology and improve lung cancer management.

PMID 42882836
Read full article →
PubMedHealthcare (Basel, Switzerland)2026-10-16

Community Pharmacy Involvement in Cardiovascular Patient Follow-Up: A Conceptual Framework for Integrated Ambulatory Pharmaceutical Care.

Santos Lúcia L, Gavina Cristina C, Oliveira Jorge J, Lima Maria João MJ et al.

Background/Objectives: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, requiring coordinated long-term management of cardiovascular risk factors, complex pharmacotherapy, and continuity of care across healthcare settings. Community pharmacists are well-placed to support ambulatory cardiovascular care; however, their contribution often remains insufficiently integrated into cardiovascular care pathways, limiting continuity, information exchange, and coordinated medication management across community, primary, and specialist care. This study aimed to establish the scientific basis for the development of an Integrated Ambulatory Pharmaceutical Follow-Up Programme in Cardiology by synthesising the available evidence on pharmacist-led cardiovascular care. Methods: An evidence-informed narrative synthesis was conducted using targeted searches of PubMed/MEDLINE, Scopus, and Web of Science, complemented by manual screening of reference lists. Priority was given to systematic reviews, meta-analyses, randomised controlled trials, and high-quality observational studies addressing pharmacist-led interventions in cardiovascular risk management, heart failure, transitions of care, cardiac rehabilitation, and integrated pharmaceutical care. Evidence was mapped across clinical outcomes, care processes, professional roles, and implementation requirements and subsequently translated into the components of the proposed integrated ambulatory care framework. Results: The available evidence consistently indicates that pharmacist-led interventions improve cardiovascular risk factor control, medication adherence, pharmacotherapy optimisation, and patient-reported outcomes. Community pharmacies provide accessible and effective settings for cardiovascular risk screening, chronic disease monitoring, and structured follow-up. In heart failure, pharmacist involvement supports optimisation of guideline-directed medical therapy, while during care transitions it contributes to the identification and reduction in medication-related problems. In cardiac rehabilitation and secondary prevention, pharmacist-led care supports medication optimisation, adherence, and cardiovascular risk-factor management. Overall, the available evidence supports the integration of community pharmacists into multidisciplinary ambulatory cardiovascular care pathways and provides the evidence base for the proposed conceptual framework. Conclusions: The proposed Integrated Ambulatory Pharmaceutical Follow-Up Programme in Cardiology provides an evidence-informed conceptual framework to support the structured integration of community pharmacists into ambulatory cardiovascular care. Its implementation has the potential to strengthen continuity of care, optimise pharmacotherapy, and support improved cardiovascular outcomes when supported by collaborative practice models, interoperable health information systems, and appropriate organisational frameworks.

PMID 42881591
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about teriparatide